Phytonadione by Cipla USA., Inc. / ScieGen Pharmaceuticals, Inc PHYTONADIONE tablet

Phytonadione by

Drug Labeling and Warnings

Phytonadione by is a Prescription medication manufactured, distributed, or labeled by Cipla USA., Inc., ScieGen Pharmaceuticals, Inc. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Phytonadione is indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity.

    • anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives;
    • hypoprothrombinemia secondary to antibacterial therapy;
    • hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis;
    • Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.
  • 2 DOSAGE AND ADMINISTRATION

    2.1 Dosing Considerations

    Avoid the oral route when the clinical disorder would prevent proper absorption. Bile salts must be given with the tablets when the endogenous supply of bile to the gastrointestinal tract is deficient. The coagulant effects of phytonadione are not immediate; improvement of international normalized ratio (INR) may take 1 to 8 hours. Interim use of whole blood or component therapy may also be necessary if bleeding is severe.

    Phytonadione will not counteract the anticoagulant action of heparin.

    When phytonadione is used to correct excessive anticoagulant-induced hypoprothrombinemia, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Phytonadione is not a clotting agent, but overzealous therapy with vitamin K1 may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and prothrombin time should be checked regularly as clinical conditions indicate.

    2.2 Recommended Dosage

    Anticoagulant-Induced Prothrombin Deficiency in Adults

    The recommended dose to correct excessively prolonged prothrombin times caused by oral anticoagulant therapy is, 2.5 mg to 10 mg or up to 25 mg initially. In some instances 50 mg may be required. Frequency and amount of subsequent doses should be determined by prothrombin time response or clinical condition. If, in 12 to 48 hours after oral administration, the prothrombin time has not been shortened satisfactorily, repeat the dose.

    Repeated large doses of phytonadione are not warranted in liver disease if the response to initial use of the vitamin is unsatisfactory. Failure to respond to phytonadione may indicate a congenital coagulation defect or that the condition being treated is unresponsive to vitamin K.

    Hypoprothrombinemia Due to Other Causes in Adults

    If possible, discontinuation or reduction of the dosage of drugs interfering with coagulation mechanisms (such as salicylates, antibiotics) is suggested as an alternative to administering concurrent phytonadione. The severity of the coagulation disorder should determine whether the immediate administration of phytonadione is required in addition to discontinuation or reduction of interfering drugs. 

    The recommended dose is 2.5 mg to 25 mg or more (sometimes up to 50 mg). Evaluate INR after 6 to 8 hours, and repeat dose if INR remains prolonged. Modify subsequent dosage (amount and frequency) based upon the INR or clinical condition.

  • 3 DOSAGE FORMS AND STRENGTHS

    Tablets: 5 mg, pale yellow colored, round, scored tablets, debossed with ‘SG 333’ on one side and score line on other side.

  • 4 CONTRAINDICATIONS

    Phytonadione is contraindicated in patients with a history of a hypersensitivity reaction to phytonadione or inactive ingredients [see Description (11)].

  • 6 ADVERSE REACTIONS

    The following adverse reactions associated with the use of parenteral phytonadione were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Severe hypersensitivity reactions, including anaphylactoid reactions and deaths, have been reported following parenteral administration. The majority of these reported events occurred following intravenous administration.

    Transient “flushing sensations” and “peculiar” sensations of taste have been observed with parenteral phytonadione, as well as instances of dizziness, rapid and weak pulse, profuse sweating, brief hypotension, dyspnea, and cyanosis.

    Hyperbilirubinemia has been observed in the newborn following administration of parenteral phytonadione. This has occurred primarily with doses above those recommended.

  • 7 DRUG INTERACTIONS

    Anticoagulants

    Phytonadione may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione are used. Should this occur, higher doses of anticoagulant therapy may be needed when resuming anticoagulant therapy, or a change in therapy to a different class of anticoagulant may be necessary (i.e., heparin sodium).

    Phytonadione does not affect the anticoagulant action of heparin.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    RiskSummary

    Published studies with the use of phytonadione during pregnancy have not reported a clear association with phytonadione and adverse developmental outcomes [see Data]. There are maternal and fetal risks associated with vitamin K deficiency during pregnancy [see Clinical Considerations]. Animal reproduction studies have not been conducted with phytonadione.

    The estimated background risk for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    Clinical Considerations

    Disease-associated maternal and/or embryo/fetal risk

    Pregnant women with vitamin K deficiency hypoprothrombinemia may be at increased risk for bleeding diatheses during pregnancy and hemorrhagic events at delivery. Subclinical vitamin K deficiency during pregnancy has been implicated in rare cases of fetal intracranial hemorrhage.

    Data

    Human Data

    Phytonadione has been measured in cord blood of infants whose mothers were treated with phytonadione during pregnancy in concentrations lower than seen in maternal plasma. Administration of vitamin K1 to pregnant women shortly before delivery increased both maternal and cord blood concentrations. Published data do not report a clear association with phytonadione and adverse maternal or fetal outcomes when used during pregnancy. However, these studies cannot definitively establish the absence of any risk because of methodologic limitations including small sample size and lack of blinding.

    Animal Data

    In pregnant rats receiving vitamin K1 orally, fetal plasma and liver concentrations increased following administration, supporting placental transfer.

    8.2 Lactation

    RiskSummary

    Phytonadione is present in breastmilk. There are no data on the effects of phytonadione on the breastfed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the clinical need for phytonadione and any potential adverse effects on the breastfed child from phytonadione or from the underlying maternal condition.

    8.4 Pediatric Use

    Safety and effectiveness in pediatric patients have not been established with phytonadione. Hemolysis, jaundice, and hyperbilirubinemia in newborns, particularly in premature infants, have been reported with vitamin K.

    8.5 Geriatric Use

    Clinical studies of phytonadione did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

  • 11 DESCRIPTION

    Phytonadione is a vitamin K replacement, which is a clear, yellow to amber, viscous, and nearly odorless liquid. It is insoluble in water, soluble in chloroform and slightly soluble in ethanol. It has a molecular weight of 450.7.

    Phytonadione is 2-methyl-3-phytyl-1, 4-naphthoquinone. Its empirical formula is C31H46O2 and its structural formula is:

    Structure

    Phytonadione tablets, USP for oral administration contain 5 mg of phytonadione, USP and are pale yellow colored, round tablets, scored on one side. Inactive ingredients are acacia, anhydrous dibasic calcium phosphate, lactose monohydrate, magnesium stearate, pregelatinized starch, silicon dioxide and talc.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Phytonadione tablets possess the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). The prothrombin test is sensitive to the levels of three of these four factors – II, VII, and X. Vitamin K is an essential cofactor for a microsomal enzyme that catalyzes the posttranslational carboxylation of multiple, specific, peptide- bound glutamic acid residues in inactive hepatic precursors of factors II, VII, IX, and X. The resulting gamma-carboxyglutamic acid residues convert the precursors into active coagulation factors that are subsequently secreted by liver cells into the blood.

    In normal animals and humans, phytonadione is virtually devoid of pharmacodynamic activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function, that is, to promote the hepatic biosynthesis of vitamin K-dependent clotting factors.

    12.2 Pharmacodynamics

    Phytonadione tablets generally exert their effect within 6 to 10 hours.

    12.3 Pharmacokinetics

    Absorption

    Oral phytonadione is adequately absorbed from the gastrointestinal tract only if bile salts are present.

    Distribution

    After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues.

    Elimination

    Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Studies of carcinogenicity or impairment of fertility have not been performed with phytonadione. Phytonadione at concentrations up to 2,000 mcg/plate, with or without metabolic activation, was negative in the Ames microbial mutagen test.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Phytonadione tablets, USP 5 mg, are pale yellow colored, round, scored tablets, debossed with ‘SG 333’ on one side and score line on other side. They are supplied as follows:

    Bottles of 30 tablets: NDC: 69097-999-02

    Bottles of 100 tablets: NDC: 69097-999-07

    Storage

    Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Always protect phytonadione from light. Store in tightly closed original container and carton until contents have been used.

  • 17 PATIENT COUNSELING INFORMATION

    Vitamin K1 is fairly rapidly degraded by light; therefore, advise patients to always protect phytonadione from light. Store phytonadione in closed original carton until contents have been used [see How Supplied/Storage and Handling (16)].


    Manufactured for:
    Cipla USA, Inc.
    10 Independence Boulevard,
    Suite 300, Warren, NJ 07059

    Manufactured by:
    ScieGen Pharmaceuticals, Inc.
    Hauppauge, NY 11788 USA

    Rev: 11/2023 

    21101736

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC 69097-999-02

    Phytonadione Tablets USP,

    5 mg

    Each tablet contains

    5 mg phytonadione, USP

    30 Tablets Rx only

    Cipla.

    Bottle label_30 tablets

    NDC 69097-999-02

    Phytonadione Tablets USP,

    5 mg

    30 Tablets Rx only

    Cipla.

    Carton label_30 tablets

    NDC 69097-999-07

    Phytonadione Tablets USP,

    5 mg

    Each tablet contains

    5 mg phytonadione, USP

    100 Tablets Rx only

    Cipla.

    Bottle label_100 tablets

    NDC 69097-999-07

    Phytonadione Tablets USP,

    5 mg

    100 Tablets Rx only

    Cipla.

    Carton label_100 tablets

  • INGREDIENTS AND APPEARANCE
    PHYTONADIONE 
    phytonadione tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 69097-999
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857) PHYTONADIONE5 mg
    Inactive Ingredients
    Ingredient NameStrength
    ACACIA (UNII: 5C5403N26O)  
    ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    TALC (UNII: 7SEV7J4R1U)  
    Product Characteristics
    Coloryellow (pale yellow) Score2 pieces
    ShapeROUNDSize6mm
    FlavorImprint Code SG;333
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 69097-999-0230 in 1 BOTTLE; Type 0: Not a Combination Product12/01/2023
    2NDC: 69097-999-07100 in 1 BOTTLE; Type 0: Not a Combination Product12/01/2023
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21332912/01/2023
    Labeler - Cipla USA., Inc. (078719707)
    Registrant - ScieGen Pharmaceuticals, Inc (079391286)
    Establishment
    NameAddressID/FEIBusiness Operations
    ScieGen Pharmaceuticals, Inc079391286manufacture(69097-999) , analysis(69097-999) , pack(69097-999) , label(69097-999)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.